Abstract:Abstract Background Fecal microbiota transplantation (FMT) shows some efficacy in treating patients with ulcerative colitis (UC), although variability has been observed among donors and treatment regimens. We investigated the effect of FMT using rationally selected donors after pretreatment with budesonide or placebo in active UC. Methods Patients ≥ 18 years old with mild to moderate active UC were randomly assigned to three weeks budesonide (9 mg) or placebo followed by four weekly infusions of a donor feces suspension. Two donors were selected based on microbiota composition, Treg induction and SCFA production in mice. The primary endpoint was engraftment of donor microbiota after FMT. In addition, clinical efficacy was assessed. Results In total, 24 patients were enrolled. Pretreatment with budesonide did not increase donor microbiota engraftment (p=0.56) nor clinical response, and engraftment was not associated with clinical response. At week 14, 10/24 (42%) of patients achieved (partial) remission. Remarkably, patients treated with FMT suspensions from one donor were associated with clinical response (80% of responders, p<0.05) but had lower overall engraftment of donor microbiota. Furthermore, differences in the taxonomic composition of the donors and the engraftment of certain taxa were associated with clinical response. Conclusion In this small study, pretreatment with budesonide did not significantly influence engraftment or clinical response after FMT. However, clinical response appeared donor-dependent. Response to FMT may be related to transfer of specific strains instead of overall engraftment, demonstrating the need to characterize mechanisms of actions of strains that maximize therapeutic benefit in ulcerative colitis.

What problem does this paper attempt to address?

This paper aims to explore the therapeutic effects of fecal microbiota transplantation (FMT) on patients with active ulcerative colitis (UC) after pretreatment with the drug budesonide or placebo. Specifically, the researchers hope to evaluate whether these measures can improve the therapeutic effect of FMT by selecting donors with a specific microbiome composition and giving patients pretreatment with budesonide or placebo before FMT, especially the engraftment of the donor microbiota in the recipient and its relationship with the clinical response. The research background indicates that FMT has shown certain efficacy in treating UC patients, but there is variability among different donors and treatment regimens. Therefore, this study specifically focuses on whether rational selection of donors (based on their microbiome composition, the ability to induce regulatory T cells (Tregs), and the ability to produce short - chain fatty acids (SCFAs)) and pretreatment with budesonide before FMT can improve the treatment effect in UC patients. The main endpoint of the study is the engraftment of the donor microbiota after FMT, and the clinical efficacy is also evaluated. Through this study, the authors hope to explore the effectiveness of FMT in treating UC, especially to determine which factors (such as donor selection, use of pretreatment drugs, etc.) may affect the therapeutic effect of FMT, thereby providing guidance for future clinical applications.

Fecal Microbiota Transplantation engraftment after budesonide or placebo in patients with active ulcerative colitis using pre-selected donors: a randomized pilot study